FDA Approves Nirsevimab-alip to Prevent RSV in Infants, Toddlers
The approval marks the first monoclonal antibody approved to protect all infants through their first respiratory syncytial virus season.
Stay updated with breaking news from Thomas Triomphe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The approval marks the first monoclonal antibody approved to protect all infants through their first respiratory syncytial virus season.
The Food and Drug Administration announced Monday it has approved a drug by which newborns and infants can be protected against respiratory syncytial virus for an entire season with a single shot.
SK bioscience successfully completed the Phase 2 clinical trial of a 21-valent pneumococcal vaccine co-developed with French biopharmaceutical company Sanofi and is on track to enter the Phase 3 trial, according to the local vaccine developer and producer, Friday.
Sanofi said that trials show the currently available mRNA technology behind the most successful COVID-19 shots will not be effective against influenza and it is already working on a next generation of shots. The French drugmaker, one of the world's largest vaccine makers, said early-stage testing on humans of its experimental influenza shot based on mRNA, or messenger RNA, showed a strong immune response against A strains of the virus but missed the mark on less prevalent B strains. Both A and B viruses are responsible for seasonal flu epidemics each year and currently available flu sho...
Sanofi, one of the top global vaccine makers, has stated that the current mRNA technology used in COVID-19 vaccines is not effective against influenza. The company is working on a next-generation flu shot based on mRNA, which showed a strong immune response against A strains but not against less prevalent B strains. Sanofi aims to upgrade the technology to improve the immune response against B strains and enhance the durability of the vaccine at normal fridge temperatures.